Rabbit Recombinant Monoclonal PVRIG/CD112R antibody. Carrier free. Suitable for WB and reacts with Mouse, Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
WB | IP | Flow Cyt | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Mouse | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Mouse, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Cell surface receptor for NECTIN2. May act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals. Following interaction with NECTIN2, inhibits T-cell proliferation. Competes with CD226 for NECTIN2-binding.
C7orf15, PVRIG, Transmembrane protein PVRIG, CD112 receptor, Poliovirus receptor-related immunoglobulin domain-containing protein, CD112R
Rabbit Recombinant Monoclonal PVRIG/CD112R antibody. Carrier free. Suitable for WB and reacts with Mouse, Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The PVRIG also known as CD112R is a cell surface receptor involved in immune responses. It has a molecular mass of approximately 38 kDa. Expressed mainly in immune cells including T cells and natural killer (NK) cells PVRIG binds with high affinity to its ligand CD112. This interaction modulates immune cell function by transmitting inhibitory signals that downregulate immune activation serving as a potential immune checkpoint.
PVRIG impacts immune cell behavior and is part of the inhibitory receptor family. Its primary role is to fine-tune the immune response by decreasing overactivation helping to maintain immune homeostasis. PVRIG interacts with other immune inhibitory receptors like TIGIT and PD-1 forming a complex network that suppresses overactive T cell responses. This process is important for preventing autoimmune reactions while allowing normal immune surveillance.
PVRIG participates in immune checkpoint pathways that influence T cell regulation. It plays a role in the immune checkpoint receptor pathway which is pivotal for controlling immune tolerance and immune-mediated inflammation. Within these pathways PVRIG works closely with other receptors like PD-1 forming a blockade that maintains the balance of immune activation and inhibition and participates in the immune synapse during antigen presentation.
PVRIG is relevant to cancer and autoimmune diseases. Its expression on T cells can be upregulated in tumor environments contributing to immune escape in cancers like melanoma. The PVRIG-CD112 interaction competes with other pathways such as TIGIT and CD112 further impacting tumor immune evasion. In autoimmune diseases PVRIG may prevent excessive immune responses linking it to conditions like rheumatoid arthritis where altered immune regulation occurs.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-PVRIG/CD112R antibody [EPR26274-202] ab307595, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Exposure times:
Lane 1: 10 seconds
Lane 2 and 3: 1 second
All lanes: Western blot - Anti-PVRIG/CD112R antibody [EPR26274-202] (Anti-PVRIG/CD112R antibody [EPR26274-202] ab307595) at 1/1000 dilution
Lane 1: Human spleen tissue lysate at 20 µg
Lane 2: Mouse spleen tissue lysate at 20 µg
Lane 3: Mouse lymph node tissue lysate at 20 µg
All lanes: Western blot at 1/2000 dilution
Observed band size: 30 kDa
This data was developed using Anti-PVRIG/CD112R antibody [EPR26274-202] ab307595, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Negative control: HeLa
Exposure time: 180 seconds.
All lanes: Western blot - Anti-PVRIG/CD112R antibody [EPR26274-202] (Anti-PVRIG/CD112R antibody [EPR26274-202] ab307595) at 1/1000 dilution
Lane 1: Daudi (human Burkitts lymphoma lymphoblast) whole cell lysate at 20 µg
Lane 2: HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 30 kDa
Exposure time: 180s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com